- Arcellx ( NASDAQ: ACLX ) shares are down 9% in late Wednesday afternoon trading. Today marks the end of the company's IPO lock-up period.
- Volume is slightly above the daily average of ~305.2K. As of 325p ET, ~401.4K shares had traded hands.
- Arcellx is focused on cancer immunotherapies. Its lead candidate is CART-ddBCMA, in phase 1 for relapsed or refractory (r/r) multiple myeloma.
- The company made its market debut in February .
- Arcellx ( ACLX ) was recently named a new buy by Canaccord Genuity .
For further details see:
Arcellx down 9% on day lock-up period ends